Total trials
911
Active
248
Phase 3
106
Total enrollment
90,710
Pipeline matrix
Showing 40 of 195 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine | — | 34 | |||||
| Pregabalin | — | — | — | — | 3 | ||
| Vonoprazan 20 mg versus Pantoprazole 40 mg | — | — | — | — | — | 1 | |
| Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg | — | — | — | — | — | 1 | |
| Bortezomib + Lenalidomide + Dexamethasone | — | — | — | — | — | 1 | |
| Co-Enzyme Q10 | — | — | — | — | — | 1 | |
| ICON resin infiltration Material group in vivo | — | — | — | — | — | 1 | |
| Resin-based fissure sealant group in vivo | — | — | — | — | — | 1 | |
| ICON resin infiltration in vitro | — | — | — | — | — | 1 | |
| Resin-based fissure sealant in vitro | — | — | — | — | — | 1 | |
| Tranexamic Acid and vitamin K | — | — | — | — | — | 1 | |
| Vitamin K 2 | — | — | — | — | — | 1 | |
| MTX SC or IM | — | — | — | — | — | 1 | |
| Empagliflozin 25mg tab | — | — | — | — | — | 1 | |
| MTX S.C or IM and Silymarin 140 mg tab | — | — | — | — | — | 1 | |
| MTX S.C or IM | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy | — | — | — | — | — | 1 | |
| Sitagliptin | — | — | — | — | — | 1 | |
| Normal saline | — | — | 21 | ||||
| Nitazoxanide | — | — | — | — | 7 | ||
| Empagliflozin | — | — | — | 4 | |||
| Levodopa Carbidopa | — | — | — | — | 3 | ||
| Saline | — | — | — | 11 | |||
| Melatonin | — | — | — | 5 | |||
| Metformin | — | — | — | — | 8 | ||
| Fluoxetine | — | — | — | — | 2 | ||
| Pentoxifylline | — | 9 | |||||
| Gabapentin | — | — | — | 6 | |||
| Magnesium sulfate | — | — | — | — | 3 | ||
| Calcitonin | — | — | — | — | 3 | ||
| Conventional treatment | — | — | — | 3 | |||
| Melatonin 10 MG | — | — | — | — | 2 | ||
| Proton Pump Inhibitor | — | — | — | — | 2 | ||
| Fexofenadine | — | — | — | — | 2 | ||
| Ketotifen | — | — | — | — | 2 | ||
| Roflumilast | — | — | — | — | — | 4 | |
| Ivermectin | — | — | — | — | 3 | ||
| Allopurinol 300 MG | — | — | — | — | — | 3 | |
| Doxycyclin | — | — | — | — | — | 2 |
155 more active programs hidden
Next readouts
- 2024-04-04
- 2024-06-20
- 2024-09-01
- 2025-01
- 2025-02-01
- 2025-02-10
- 2025-03-10
- 2025-03-10
- 2025-03-25
- 2025-04-01
Top conditions
- Dexmedetomidine33
- Analgesia23
- Erector Spinae Plane Block19
- Postoperative Analgesia18
- Sepsis16
- Ultrasound16
- Postoperative Pain15
- Pain13
Frequently asked questions about Tanta University
- How many clinical trials does Tanta University have on ClinicalTrials.gov?
- Tanta University is listed as the lead sponsor on 911 clinical trials in ClinicalTrials.gov, 248 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Tanta University's trials are in Phase 3?
- 106 of Tanta University's trials are in Phase 3, spread across 195 active drug programs.
- What therapeutic areas does Tanta University focus on?
- Tanta University's most-studied conditions on ClinicalTrials.gov are Dexmedetomidine, Analgesia, Erector Spinae Plane Block, Postoperative Analgesia, Sepsis.
- When are Tanta University's next clinical trial readouts?
- Tanta University has 10 upcoming primary-completion readouts tracked here; the soonest is “The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy”, expected around 2024-04-04.